Loading clinical trials...

The Use of Residual De-identified Specimens and/or Samples From Patients for Clinical Research | Clinical Trials | Clareo Health

RECRUITING

The Use of Residual De-identified Specimens and/or Samples From Patients for Clinical Research

NCT06222164•Invivoscribe, Inc.

View on ClinicalTrials.gov

Summary

Acquire residual human specimens and/or samples from patient samples which were sent for testing at LabPMM, LLC for Clinical Research

Detailed Description

Residual specimen/sample collection study where peripheral blood (PB), bone marrow (BM), genomic (gDNA), and/or formalin-fixed paraffin-embedded tissue (FFPE) specimens/samples are obtained from patient samples sent to LabPMM, LLC for clinical testing. Samples may be used for Clinical Research at LabPMM, LLC or at partner institutions

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Specimen/sample, peripheral blood (PB), bone marrow (BM), genomic DNA (gDNA) and/or formalin-fixed paraffin-embedded tissue (FFPE) from patients whose specimens/samples have been sent to LabPMM for clinical testing
•2. Donor Age ≥ 18 years

Exclusion Criteria

•1. Sample/specimen has been obtained from a third-party vendor with a Materials Transfer Agreement (MTA) on file with LabPMM
•2. The specimens/samples have previously been enrolled in a clinical study

Locations (1)

LabPMM

San Diego, California, United States

Key Dates

Start Date

March 30, 2024

Primary Completion Date

March 30, 2027

Completion Date

June 30, 2027

Last Updated

May 4, 2025

Enrollment

2,000

ESTIMATED participants

Conditions

Hematologic Diseases

Contacts

Andrew Schut

CONTACT

+1 858.224.6600 aschut@invivoscribe.com

The Implementation of the Go Wish Game to Promote Advance Care Planning in Onco- Hematologic Disease

NCT06795815

LeukemiaMultiple Mieloma+4 more

View study

RECRUITINGNA

MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing

NCT05794880

LeukemiaAcute Myeloid Leukemia in Remission+11 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 4, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

The Use of Residual De-identified Specimens and/or Samples From Patients for Clinical Research

Inclusion Criteria

Exclusion Criteria

The Implementation of the Go Wish Game to Promote Advance Care Planning in Onco- Hematologic Disease

MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing

Bleeding Events Before vs After Lowering Departmental Platelet Transfusion Trigger

Diagnosis and Phenotype Characterisation Using Genomics in Patients With Inherited Bone Marrow Failure (IBMDx Study)

A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study

Advancing Health Information Exchange (HIE) During Inter-hospital Transfer (IHT) to Improve Patient Outcomes